NEW YORK (Reuters Health) – Basal bolus glargine insulin once daily plus glulisine before meals effectively manages general surgery patients with type 2 diabetes, investigators report. Compared to…
NEW YORK (Reuters Health) – Depending on the particular regimen, insulin analogs can help 35% to 64% of patients with type 2 diabetes achieve the recommended hemoglobin A1C…
NEW YORK (Reuters Health) – In a small study of pregnant women with type 1 diabetes, use of a closed-loop insulin delivery system (also known as the artificial…
NEW YORK (Reuters Health) – The mineralocorticoid receptor blocker eplerenone has advantages over spironolactone in the treatment of chronic heart failure (CHF), a Japanese team reports. In particular,…
NEW YORK (Reuters Health) – Elevated systolic blood pressure and low diastolic blood pressure are associated with increased risk of cardiovascular disease (CVD) among patients with type 2…
NEW YORK (Reuters Health) – The GLP-1 receptor agonist exenatide used to treat type 2 diabetes is associated with a lower risk of cardiovascular disease (CVD) events, compared…
NEW YORK (Reuters Health) – Using the rapid-acting insulin analog glulisine instead of regular human insulin at mealtimes improves glycemic control in hospitalized patients with type 2 diabetes,…
NEW YORK (Reuters Health) – When patients with rheumatic illnesses and concomitant diabetes are treated with hydroxychloroquine, their HbA1c levels drop significantly. Methotrexate, however, does not have the…
NEW YORK (Reuters Health) – As soon as 2 years after diagnosis, children and adolescents with type 2 diabetes require increasing doses of insulin — reflecting a more…
NEW YORK (Reuters Health) – The combination of the dipeptidyl peptidase (DPP)-4 inhibitor alogliptin and the thiazolidinedione pioglitazone effectively reduces HbA1c in patients with type 2 diabetes uncontrolled…